Just before Versant and venBio officially took the wraps off RayzeBio with $45 million in launch money, Ken Song reached out to a few other investors “just to give them an overview.”
He wasn’t necessarily looking to raise money immediately, the CEO said. Whereas the Series A came together mostly around the concept of a new radiopharmaceutical company, RayzeBio now had more details and progress around its pipeline to illustrate just what its platform can do. But the group — comprising some firms that were known for their crossover and public portfolios — became so enthused that, barely two months later, he has $105 million more to work with.
